|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Roggli VL, Vollmer RT, Greenberg SD,
McGavran MH, Spjut HJ and Yesner R: Lung cancer heterogeneity: a
blinded and randomized study of 100 consecutive cases. Hum Pathol.
16:569–579. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kuwabara K, Matsuda S, Fushimi K, et al:
Differences in practice patterns and costs between small cell and
non-small cell lung cancer patients in Japan. Tohoku J Exp Med.
217:29–35. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gazdar AF: Epidermal growth factor
receptor inhibition in lung cancer: the evolving role of
individualized therapy. Cancer Metastasis Rev. 29:37–48. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, et al: Erlotinib in previously treated non-small-cell lung
cancer. N Engl J Med. 353:123–132. 2005.PubMed/NCBI
|
|
6
|
Pao W, Miller VA, Politi KA, et al:
Acquired resistance of lung adenocarcinomas to gefitinib or
erlotinib is associated with a second mutation in the EGFR kinase
domain. PLoS Med. 2:e732005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vanhaesebroeck B, Guillermet-Guibert J,
Graupera M and Bilanges B: The emerging mechanisms of
isoform-specific PI3K signalling. Nat Rev Mol Cell Biol.
11:329–341. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Luo J, Manning BD and Cantley LC:
Targeting the PI3K-Akt pathway in human cancer: rationale and
promise. Cancer Cell. 4:257–262. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Engelman JA: Targeting PI3K signalling in
cancer: opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Janmaat ML, Kruyt FA, Rodriguez JA and
Giaccone G: Response to epidermal growth factor receptor inhibitors
in non-small cell lung cancer cells: limited antiproliferative
effects and absence of apoptosis associated with persistent
activity of extracellular signal-regulated kinase or Akt kinase
pathways. Clin Cancer Res. 9:2316–2326. 2003.
|
|
12
|
Engelman JA, Jänne PA, Mermel C, et al:
ErbB-3 mediates phosphoinositide 3-kinase activity in
gefitinib-sensitive non-small cell lung cancer cell lines. Proc
Natl Acad Sci USA. 102:3788–3793. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamasaki F, Johansen MJ, Zhang D, et al:
Acquired resistance to erlotinib in A-431 epidermoid cancer cells
requires down-regulation of MMAC1/PTEN and up-regulation of
phosphorylated Akt. Cancer Res. 67:5779–5788. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Engelman JA, Chen L, Tan X, et al:
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D
and PIK3CA H1047R murine lung cancers. Nat Med. 14:1351–1356. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Samuels Y, Wang Z, Bardelli A, et al: High
frequency of mutations of the PIK3CA gene in human cancers.
Science. 304:5542004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee H, Jung KH, Jeong Y, Hong S and Hong
SS: HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor,
has anti-tumor activity through promoting apoptosis and inhibiting
angiogenesis. Cancer Lett. 328:152–159. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim O, Jeong Y, Lee H, Hong SS and Hong S:
Design and synthesis of imidazopyridine analogues as inhibitors of
phosphoinositide 3-kinase signaling and angiogenesis. J Med Chem.
54:2455–2466. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alvarez M, Roman E, Santos ES and Raez LE:
New targets for non-small-cell lung cancer therapy. Expert Rev
Anticancer Ther. 7:1423–1437. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pao W, Miller V, Zakowski M, et al: EGF
receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
|
|
20
|
Bast RC, Kufe DW, Pollock RE, et al:
Cancer of the lung. Holland-Frei Cancer Medicine. 5th edition. BC
Decker Publishing Inc; Hamilton, ON: 2000
|
|
21
|
Yang L, Dan HC, Sun M, et al: Akt/protein
kinase B signaling inhibitor-2, a selective small molecule
inhibitor of Akt signaling with antitumor activity in cancer cells
overexpressing Akt. Cancer Res. 64:4394–4399. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Workman P: Inhibiting the phosphoinositide
3-kinase pathway for cancer treatment. Biochem Soc Trans.
32:393–396. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schultz RM, Merriman RL, Andis SL, et al:
In vitro and in vivo antitumor activity of the
phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer
Res. 15:1135–1139. 1995.PubMed/NCBI
|
|
24
|
Rowinsky EK: Targeting the molecular
target of rapamycin (mTOR). Curr Opin Oncol. 16:564–575. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lindqvist A, Rodriguez-Bravo V and Medema
RH: The decision to enter mitosis: feedback and redundancy in the
mitotic entry network. J Cell Biol. 185:193–202. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tyagi A, Singh RP, Agarwal C, Siriwardana
S, Sclafani RA and Agarwal R: Resveratrol causes Cdc2-tyr15
phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central
mechanism for S phase arrest in human ovarian carcinoma Ovcar-3
cells. Carcinogenesis. 26:1978–1987. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kuo PL, Hsu YL and Cho CY: Plumbagin
induces G2-M arrest and autophagy by inhibiting the AKT/mammalian
target of rapamycin pathway in breast cancer cells. Mol Cancer
Ther. 5:3209–3221. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
O'Farrell PH: Triggering the
all-or-nothing switch into mitosis. Trends Cell Biol. 11:512–519.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cuddihy AR and O'Connell MJ: Cell-cycle
responses to DNA damage in G2. Int Rev Cytol. 222:99–140. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hirose Y, Katayama M, Mirzoeva OK, Berger
MS and Pieper RO: Akt activation suppresses Chk2-mediated,
methylating agent-induced G2 arrest and protects from
temozolomide-induced mitotic catastrophe and cellular senescence.
Cancer Res. 65:4861–4869. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang X and Proud CG: The mTOR pathway in
the control of protein synthesis. Physiology (Bethesda).
21:362–369. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ashe PC and Berry MD: Apoptotic signaling
cascades. Prog Neuropsychopharmacol Biol Psychiatry. 27:199–214.
2003. View Article : Google Scholar
|
